SYRE Earnings Spyre Therapeutics, Inc.
Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Latest filing
Annual results
EPS
Revenue
Net income
Quarterly results
EPS
Revenue
Net income
Reported EPS history
1–18 of 18
| Q1 2026 | 2026-03-31 | -0.74 | 2026-05-05 | 10-Q |
| Q3 2024 | 2024-09-30 | -1.36 | 2024-11-07 | 10-Q |
| Q2 2024 | 2024-06-30 | -0.86 | 2024-08-07 | 10-Q |
| Q1 2024 | 2024-03-31 | -1.20 | 2024-05-09 | 10-Q |
| Q4 2023 (derived) | 2023-12-31 | 21.90 | 2024-02-29 | 10-K |
| FY 2023 | 2023-12-31 | -49.12 | 2024-02-29 | 10-K |
| Q3 2023 | 2023-09-30 | -9.34 | 2023-11-09 | 10-Q |
| Q2 2023 | 2023-06-30 | -56.79 | 2023-08-11 | 10-Q |
| Q1 2023 | 2023-03-31 | -4.89 | 2023-05-11 | 10-Q |
| Q4 2022 (derived) | 2022-12-31 | -4.02 | 2023-03-02 | 10-K |
| FY 2022 | 2022-12-31 | -24.86 | 2023-03-02 | 10-K |
| Q3 2022 | 2022-09-30 | -4.84 | 2022-11-03 | 10-Q |
| Q2 2022 | 2022-06-30 | -6.75 | 2022-08-04 | 10-Q |
| Q1 2022 | 2022-03-31 | -9.25 | — | — |
| FY 2021 | 2021-12-31 | -25.02 | — | — |
| Q3 2021 | 2021-09-30 | -7.75 | — | — |
| Q2 2021 | 2021-06-30 | -2.50 | — | — |
| FY 2020 | 2020-12-31 | -38.00 | — | — |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Q4 EPS marked "derived" is computed as the fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive across quarters, so it can differ by a cent or two from the issuer's own Q4. A period with no "Reported" date is known only from a later filing's prior-year comparative. Informational only — not financial advice.